Phase 2 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose body weight falls within a healthy range for their height (a BMI between 18.0 and 35.0) at the time of their screening appointment
- People who are not currently pregnant or breastfeeding
- People who are willing and able to sign a consent form before any study procedures begin
- People who are able to use highly effective contraception plus a condom throughout the study and for at least 90 days after the study ends or after the last dose of study medication, whichever is later, and who agree not to donate sperm or eggs during that same period
- Adults between 50 and 80 years of age who have received a clinical diagnosis of early Alzheimer's disease (AD), supported by blood, spinal fluid, or brain imaging results that are consistent with that diagnosis
- People already taking Alzheimer's medications where the dose has been stable for at least 8 weeks before the screening appointment (people with early AD are not required to be on these medications)
- People who have a reliable caregiver or trusted support person aged 18 or older who is willing to attend certain study visits, be available by phone when needed, and who knows the participant well enough to provide accurate information about them throughout the study
Who may not be able to join:
- People whose blood pressure falls outside the range specified in the study protocol
- People who test positive for HIV at the screening appointment
- People who test positive for hepatitis B or hepatitis C at the screening appointment
- People who have an intellectual disability or significant behavioural or psychiatric symptoms
- People with a clinically significant heart, liver, or kidney condition
- People for whom a lumbar puncture (spinal tap) would not be medically appropriate
- People who are known to be allergic, or may be allergic, to the study drug (ARO-MAPT-SC) or any of its ingredients
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 626-304-3400
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Over Time
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.